Serum evaluation of soluble interferon-α/β receptor and high-sensitivity C-reactive protein for diagnosis of the patients with gastrointestinal and hepatobiliary-pancreatic cancer

Cytokine

Volumn 49, Issue 3, 2010, Pages 251-255

  Miyake, Kotaro ^a   Imura, Satoru ^a   Nishioka, Masanori ^a   Batmunkh, Erdenebulgan ^a   Sugimoto, Koji ^a   Ohmoto, Yasukazu ^b   Shimada, Mitsuo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Enzyme linked immunosorbent assay; Gastrointestinal and hepatobiliary pancreatic cancer; High sensitivity C reactive protein; Soluble interferon receptor

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA INTERFERON RECEPTOR; C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; BILIARY TRACT CANCER; BLOOD ANALYSIS; COLON CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELIABILITY; SENSITIVITY AND SPECIFICITY; SOLUBILITY; STOMACH CANCER; VALIDITY;

ADULT; AGED; AGED, 80 AND OVER; BILIARY TRACT NEOPLASMS; C-REACTIVE PROTEIN; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; RECEPTOR, INTERFERON ALPHA-BETA; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 75449088975     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.09.010     Document Type: Article

References (55)

1. Sandeman T.F., and Boyne P. Tumour markers. A clinical review. Aust Fam Physician 14 (1985) 420-426
2. van den Berg G.A., Nagel G.T., Muskiet F.A., and Halie M.R. Mass fragmentographic identification of polyamine metabolites in the urine of normal persons and cancer patients, and its relevance to the use of polyamines as tumour markers. J Chromatogr 339 (1985) 223-231
3. Klavins J.V. Tumour markers. Lancet 1 (1986) 745-746
4. Wanebo H.J., Rao B., Pinsky C.M., Hoffman R.G., Stearns M., Schwartz M.K., et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 299 (1978) 448-451
5. Babaian R.J., and Orlando R.P. Elevated prostatic acid phosphatase: a prognostic factor for stage C adenocarcinoma of the prostate. J Urol 136 (1986) 1035-1037
6. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 (2001) 539-545
7. Pisa P., Halapi E., Pisa E.K., Gerdin E., Hising C., Bucht A., et al. Selective expression of interleukin 10, gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc Natl Acad Sci USA 89 (1992) 7708-7712
8. Chekerov R., Klaman I., Zafrakas M., Konsgen D., Mustea A., Petschke B., et al. Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. Neoplasia 8 (2006) 38-45
9. Koensgen D., Mustea A., Denkert C., Sun P.M., Lichtenegger W., and Sehouli J. Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer. Anticancer Res 26 (2006) 1683-1689
10. Berek J.S., and Martinez-Maza O. Molecular and biologic factors in the pathogenesis of ovarian cancer. J Reprod Med 39 (1994) 241-248
11. Mocellin S., Wang E., and Marincola F.M. Cytokines and immune response in the tumor microenvironment. J Immunother 24 (2001) 392-407
12. Bozcuk H., Uslu G., Samur M., Yildiz M., Ozben T., Ozdogan M., et al. Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine 27 (2004) 58-65
13. Mustea A., Braicu E.I., Koensgen D., Yuan S., Sun P.M., Stamatian F., et al. Monitoring of IL-10 in the serum of patients with advanced ovarian cancer: results from a prospective pilot-study. Cytokine 45 (2009) 8-11
14. Pappa C., Miyakis S., Tsirakis G., Sfiridaki A., Alegakis A., Kafousi M., et al. Serum levels of interleukin-15 and interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma. Cytokine 37 (2007) 171-175
15. Dansky-Ullmann C., Salgaller M., Adams S., Schlom J., and Greiner J.W. Synergistic effects of IL-6 and IFN-gamma on carcinoembryonic antigen (CEA) and HLA expression by human colorectal carcinoma cells: role for endogenous IFN-beta. Cytokine 7 (1995) 118-129
16. Song B.C., Chung Y.H., Kim J.A., Choi W.B., Suh D.D., Pyo S.I., et al. Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 94 (2002) 175-180
17. Mizukoshi E., Kaneko S., Kaji K., Terasaki S., Matsushita E., Muraguchi M., et al. Serum levels of soluble interferon alfa/beta receptor as an inhibitory factor of interferon in the patients with chronic hepatitis C. Hepatology 30 (1999) 1325-1331
18. Solberg H.E. Textbook of clinical chemistry (1986), W.B. Saunders Company, Lexington p. 356-409
19. Ambrus J.L., Ambrus Jr. J.L., Chadha S., Novick D., Rubinstein M., Gopalakrishnan B., et al. Mechanism(s) of interferon inhibitory activity in blood from patients with AIDS and patients with lupus erythematosus with vasculitis. Res Commun Mol Pathol Pharmacol 96 (1997) 255-265
20. Ambrus Sr. J.L., Dembinski W., Ambrus Jr. J.L., Sykes D.E., Akhter S., Kulaylat M.N., et al. Free interferon-alpha/beta receptors in the circulation of patients with adenocarcinoma. Cancer 98 (2003) 2730-2733
21. Ridker P.M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103 (2001) 1813-1818
22. Dash S., Prabhu R., Hazari S., Bastian F., Garry R., Zou W., et al. Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation. Liver Int 25 (2005) 580-894
23. Theofilopoulos A.N., Baccala R., Beutler B., and Kono D.H. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23 (2005) 307-336
24. Bekisz J., Schmeisser H., Hernandez J., Goldman N.D., and Zoon K.C. Human interferons alpha, beta and omega. Growth Factors 22 (2004) 243-251
25. Rosewicz S., Detjen K., Scholz A., and von Marschall Z. Interferon-alpha: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology 80 Suppl. 1 (2004) 85-93
26. Tedjarati S., Baker C.H., Apte S., Huang S., Wolf J.K., Killion J.J., et al. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel. Clin Cancer Res 8 (2002) 2413-2422
27. Domanski P., Witte M., Kellum M., Rubinstein M., Hackett R., Pitha P., et al. Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling. J Biol Chem 270 (1995) 21606-21611
28. Lutfalla G., Holland S.J., Cinato E., Monneron D., Reboul J., Rogers N.C., et al. Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J 14 (1995) 5100-5108
29. Novick D., Cohen B., and Rubinstein M. The human interferon alpha/beta receptor: characterization and molecular cloning. Cell 77 (1994) 391-400
30. Uze G., Lutfalla G., and Gresser I. Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA. Cell 60 (1990) 225-234
31. Novick D., Cohen B., and Rubinstein M. Soluble interferon-alpha receptor molecules are present in body fluids. FEBS Lett 314 (1992) 445-448
32. Novick D., Cohen B., Tal N., and Rubinstein M. Soluble and membrane-anchored forms of the human IFN-alpha/beta receptor. J Leukoc Biol 57 (1995) 712-718
33. Gabay C., and Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340 (1999) 448-454
34. Mendall M.A., Patel P., Asante M., Ballam L., Morris J., Strachan D.P., et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 78 (1997) 273-277
35. de Mello J., Struthers L., Turner R., Cooper E.H., and Giles G.R. Multivariate analyses as aids to diagnosis and assessment of prognosis in gastrointestinal cancer. Br J Cancer 48 (1983) 341-348
36. Stamatiadis A.P., Manouras A.J., Triantos G.N., Katergiannakis V.A., and Apostolidis N.S. Combination of serum carcino-embryonic antigen and C-reactive protein - a useful test in preoperative staging of colorectal cancer. Eur J Surg Oncol 18 (1992) 41-43
37. McMillan D.C., Wotherspoon H.A., Fearon K.C., Sturgeon C., Cooke T.G., and McArdle C.S. A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg 170 (1995) 319-322
38. Nozoe T., Matsumata T., Kitamura M., and Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 176 (1998) 335-338
39. Fujita T., Hara A., and Yamazaki Y. The value of acute-phase protein measurements after curative gastric cancer surgery. Arch Surg 134 (1999) 73-75
40. Nielsen H.J., Christensen I.J., Sorensen S., Moesgaard F., and Brunner N. Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol 7 (2000) 617-623
41. Wigmore S.J., McMahon A.J., Sturgeon C.M., and Fearon K.C. Acute-phase protein response, survival and tumour recurrence in patients with colorectal cancer. Br J Surg 88 (2001) 255-260
42. Nozoe T., Saeki H., and Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 182 (2001) 197-201
43. Hashimoto K., Ikeda Y., Korenaga D., Tanoue K., Hamatake M., Kawasaki K., et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 103 (2005) 1856-1864
44. Miyata Y., Koga S., Nishikido M., Noguchi M., Kanda S., Hayashi T., et al. Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology 58 (2001) 161-164
45. Kodama J., Miyagi Y., Seki N., Tokumo K., Yoshinouchi M., Kobashi Y., et al. Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 82 (1999) 107-110
46. Sezer O., Niemoller K., Eucker J., Jakob C., Kaufmann O., Zavrski I., et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol 79 (2000) 574-577
47. Singh S.K., Suresh M.V., Voleti B., and Agrawal A. The connection between C-reactive protein and atherosclerosis. Ann Med 40 (2008) 110-120
48. Wilson A.M., Ryan M.C., and Boyle A.J. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol 106 (2006) 291-297
49. Otani T., Iwasaki M., Sasazuki S., Inoue M., and Tsugane S. Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev 15 (2006) 690-695
50. Cengiz M., Akbulut S., Atahan I.L., and Grigsby P.W. Acute phase response during radiotherapy. Int J Radiat Oncol Biol Phys 49 (2001) 1093-1096
51. Agroyannis B., Dardoufas C., Vitoratos N., Tzanatos H., Kouvaris J., Damatopoulou A., et al. Changes of serum transferrin and ceruloplasmin after radiation therapy in women with cervical or uterine carcinoma. Clin Exp Obstet Gynecol 21 (1994) 24-27
52. Agroyannis B., Kouvaris J., Tzanatos H., Chondros K., Stringou E., Damatopoulou A., et al. Influence of radiation treatment on serum transferrin and tumor necrosis factor-alpha. Anticancer Res 12 (1992) 1757-1759
53. Flamini E., Mercatali L., Nanni O., Calistri D., Nunziatini R., Zoli W., et al. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin Cancer Res 12 (2006) 6985-6988
54. Camlica H., Duranyildiz D., Oguz H., Oral E.N., and Yasasever V. The diagnostic value of macrophage migration inhibitory factor (MIF) in gastric cancer. Pathol Oncol Res 14 (2008) 79-83
55. Pipinikas C.P., Carter N.D., Corbishley C.M., and Fenske C.D. HIF-1alpha mRNA gene expression levels in improved diagnosis of early stages of prostate cancer. Biomarkers 13 (2008) 680-691